搜索

x

肝癌、肝硬化及慢性肝炎患者血脂及载脂蛋白AI、B100水平的变化

Variation of Serum Lipid Apoprotein AI、B100 in Patients With Liver Cancer Cirrhosic and Chronis Hepatitis

  • 摘要: 本文对31例肝癌、30例肝硬化及31例慢性肝炎患者进行了血清载脂蛋白(apo)AI、B100及血脂的检测, 并与63例健康成人作比较. 结果表明: 肝癌、肝硬化及慢性肝炎患者血清总胆固醇(TC)、高密度脂蛋白胆固醇(HDL—C)和apo AI都显著的降低, 与健康对照组比较, 均有极显著性差异(P<0.001); 肝癌及肝硬化患者血清甘油三酯(TC)都呈不同程度的降低(P<0.01和P<0.05); 肝硬化患者的血清apo B100也显著的降低(P<0.001). 本文资料提示, 在肝脏疾病时检测血脂及apo AI、B100含量, 可以了解肝实质损伤的程度.

     

    Abstract: In this paper, the serum apoprotein AI、B100 and lipid are analysed in thirty one cases of liver cancer, thirty cases of liver cirrhosis and thirty one cases of chronic hepatitis, and they are compared with the ones resulted from 63 healthy adults. The results show that the total serum cholesterol, cholesterol in high density lipid protein and apoprotein AI in the group of patients decrease significantly, and the difference is statistically significant (P<0.001). The serum triglyceride decreases in liver cancer patients and cirrhosis patients (P<0.01 and P<0.05). The serum apoprotein B100 also decreases significantly (P<0.001) in cirrhosis patients. The results indicate that measurement of serum lipid, apoprotein AI and B100 may be useful in estimating the magnitude of liver damage.

     

/

返回文章
返回